Physician profile
Devesh Patel
NPI 1316902943
$6,259.55
in general payments reported to CMS, 2019-2025
33 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $702 · 2020: $311 · 2021: $1,624 · 2022: $902 · 2023: $1,047 · 2024: $1,220 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,626 · Education: $94.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,626.29 |
| Education | $94.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $568.81 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $527.17 | 2019-2024 | Farxiga, Lokelma |
| Amgen INC. | $492.33 | 2019-2025 | Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $442.20 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $409.62 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $392.24 | 2020-2022 | |
| Aurinia Pharma U.S., INC. | $379.30 | 2021-2025 | Lupkynis |
| Vifor Pharma, INC. | $343.57 | 2019-2024 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $288.32 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $277.64 | 2019-2024 | Velphoro, Korsuva |
| Opko Pharmaceuticals, LLC | $272.05 | 2019-2023 | Rayaldee |
| Glaxosmithkline, LLC. | $250.50 | 2021-2025 | Benlysta |
| Daiichi Sankyo INC. | $244.90 | 2019-2024 | Injectafer |
| Horizon Therapeutics Plc | $236.63 | 2021-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $184.82 | 2019-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $181.06 | 2020-2024 | Gattex |
| Travere Therapeutics, INC. | $162.05 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $155.46 | 2019-2024 | Ultomiris |
| Lilly USA, LLC | $70.30 | 2024 | Jardiance, Mounjaro |
| Ani Pharmaceuticals, INC. | $56.61 | 2022-2024 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $44.90 | 2020-2024 | Vafseo |
| Novo Nordisk INC | $44.58 | 2024-2025 | Ozempic, Rybelsus |
| Ultragenyx Pharmaceutical INC. | $33.77 | 2021-2023 | |
| Shire North American Group INC | $30.04 | 2019 | |
| Cormedix INC. | $29.26 | 2024 | Defencath |
| Pfizer INC. | $27.40 | 2024 | |
| Mallinckrodt Enterprises LLC | $26.53 | 2019 | |
| Ardelyx, INC. | $20.24 | 2024 | Ibsrela |
| Mannkind Corporation | $18.09 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.23 | 2024 | Jardiance |
| Abbvie INC. | $17.06 | 2021 | |
| W. L. Gore & Associates, INC. | $14.87 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.